*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | Update on Neuroprotection after Traumatic Brain Injury CNS drugs · preclinical | PMID 40087248 |
| 2025 | Cost-effectiveness of Cerebrolysin as an add-on treatment for neurorecovery after traumatic brain injury Journal of medicine and life · preclinical | PMID 40405935 |
| 2025 | Combined citicoline and Cerebrolysin for neuroprotection in traumatic brain injury: a retrospective cohort analysis Frontiers in neurology · preclinical | PMID 41409218 |
| 2024 | Neuroprotective and neuroregenerative drugs after severe traumatic brain injury : A narrative review from a clinical perspective Wiener klinische Wochenschrift · preclinical | PMID 38748062 |
| 2024 | Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis Frontiers in neuroscience · preclinical | PMID 39834702 |
| 2024 | Current neuroprotective agents in stroke Turkish journal of physical medicine and rehabilitation · preclinical | PMID 38948647 |
| 2024 | [Traumatic brain injury as risk factor of Alzheimer's disease and possibilities of pathogenetic therapy] Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · preclinical | PMID 38261283 |
| 2023 | Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin Medicinal research reviews · preclinical | PMID 37052231 |
| 2023 | Cerebrolysin for acute ischaemic stroke The Cochrane database of systematic reviews · preclinical | PMID 37818733 |
| 2023 | Cerebrolysin and repetitive transcranial magnetic stimulation (rTMS) in patients with traumatic brain injury: a three-arm randomized trial Frontiers in neuroscience · preclinical | PMID 37360156 |
| 2023 | Nanowired delivery of antibodies to tau and neuronal nitric oxide synthase together with cerebrolysin attenuates traumatic brain injury induced exacerbation of brain pathology in Parkinson's disease International review of neurobiology · preclinical | PMID 37783564 |
| 2022 | Cerebrolysin alleviates early brain injury after traumatic brain injury by inhibiting neuroinflammation and apoptosis via TLR signaling pathway Acta cirurgica brasileira · preclinical | PMID 36074398 |
| 2022 | Effect of Cerebrolysin in severe traumatic brain injury: A multi-center, retrospective cohort study Clinical neurology and neurosurgery · preclinical | PMID 35344761 |
| 2021 | Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · preclinical | PMID 33515100 |
| 2021 | Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · preclinical | PMID 33620612 |
| 2021 | Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide Progress in brain research · preclinical | PMID 34560919 |
| 2020 | Mild traumatic brain injury exacerbates Parkinson's disease induced hemeoxygenase-2 expression and brain pathology: Neuroprotective effects of co-administration of TiO(2) nanowired mesenchymal stem cells and cerebrolysin Progress in brain research · preclinical | PMID 33223035 |
| 2019 | Cerebrolysin for vascular dementia The Cochrane database of systematic reviews · preclinical | PMID 31710397 |
| 2017 | Cerebrolysin for acute ischaemic stroke The Cochrane database of systematic reviews · preclinical | PMID 28430363 |
| 2012 | Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials Drugs of today (Barcelona, Spain : 1998) · preclinical | PMID 22514795 |
Cerebrolysin (Cerebrolysin (porcine-brain-derived peptide preparation)). Mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain protein; proposed neurotrophic/neuroprotective action mimicking endogenous growth factors.
Commonly discussed uses: stroke, traumatic brain injury, dementia adjunct (approved in some countries). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain protein; proposed neurotrophic/neuroprotective action mimicking endogenous growth factors.
Reported considerations: injection-site reaction, rare: agitation, dizziness, hypersensitivity risk (porcine-derived). There is both human and animal/preclinical research, though the depth and quality vary by indication. Marketed/approved in some countries (e.g. parts of Europe/Asia); not approved in AU/US/UK. Clinical evidence is mixed. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 5ml/day, typical 10-30ml/day IV/IM in clinical courses, high up to 50ml/day (clinical). Administration: intravenous, intramuscular. Half-life: mixture — not a single value.
Australian status: Not ARTG-registered. Marketed/approved in some countries (e.g. parts of Europe/Asia); not approved in AU/US/UK. Clinical evidence is mixed. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: supplied as ampoule solution (no reconstitution); storage: room temp per product; protect from light.
Commonly discussed combinations (anecdotal for unapproved compounds): clinical courses standalone. Stacking increases interaction/safety uncertainty.